172 related articles for article (PubMed ID: 37788005)
1. Identification and validation of obesity related genes signature based on microenvironment phenotypes in prostate adenocarcinoma.
Liang L; Shang J; Zhang Y; Xu Y; Zhouteng Y; Wen J; Zhao Y; Feng N; Zhao R
Aging (Albany NY); 2023 Oct; 15(19):10168-10192. PubMed ID: 37788005
[TBL] [Abstract][Full Text] [Related]
2. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
Front Immunol; 2022; 13():964393. PubMed ID: 36211344
[TBL] [Abstract][Full Text] [Related]
3. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
4. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
5. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
Chen L; Zhang M; Zhou J; Zhang L; Liang C
Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
[TBL] [Abstract][Full Text] [Related]
6. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
[TBL] [Abstract][Full Text] [Related]
7. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
[TBL] [Abstract][Full Text] [Related]
8. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
[TBL] [Abstract][Full Text] [Related]
9. A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma.
Liu J; Tan Z; Yang S; Song X; Li W
Aging (Albany NY); 2022 Sep; 14(17):7170-7185. PubMed ID: 36103249
[TBL] [Abstract][Full Text] [Related]
10. Characterization of metabolism-associated molecular patterns in prostate cancer.
Yang B; Jiang Y; Yang J; Zhou W; Yang T; Zhang R; Xu J; Guo H
BMC Urol; 2023 Jun; 23(1):104. PubMed ID: 37280589
[TBL] [Abstract][Full Text] [Related]
11. Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.
Zhao HB; Zeng YR; Han ZD; Zhuo YJ; Liang YK; Hon CT; Wan S; Wu S; Dahl D; Zhong WD; Wu CL
Cancer Sci; 2021 Oct; 112(10):4365-4376. PubMed ID: 34252262
[TBL] [Abstract][Full Text] [Related]
12. Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas.
Zhao X; Hu D; Li J; Zhao G; Tang W; Cheng H
Biomed Res Int; 2020; 2020():5019793. PubMed ID: 32509861
[TBL] [Abstract][Full Text] [Related]
13. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma.
Liang L; Xia W; Yao L; Wu Q; Hua L; Cheng G; Wang Z; Zhao R
Int Immunopharmacol; 2021 Dec; 101(Pt A):108267. PubMed ID: 34740081
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel stemness-related signature with appealing implications in discriminating the prognosis and therapy responses for prostate cancer.
Zhang T; Li J; Dai J; Yuan F; Yuan G; Chen H; Zhu D; Mao X; Qin L; Liu N; Yang M
Cancer Genet; 2023 Aug; 276-277():48-59. PubMed ID: 37487324
[TBL] [Abstract][Full Text] [Related]
16. High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration.
Piao S; Zheng L; Zheng H; Zhou M; Feng Q; Zhou S; Ke M; Yang H; Wang X
J Immunol Res; 2022; 2022():2922832. PubMed ID: 35707002
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
[TBL] [Abstract][Full Text] [Related]
18. A N
Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
[TBL] [Abstract][Full Text] [Related]
19. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
Front Immunol; 2021; 12():791924. PubMed ID: 34975891
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
